Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 25;8(7):75.
doi: 10.3390/jcdd8070075.

Early Aberrant Angiogenesis Due to Elastic Fiber Fragmentation in Aortic Valve Disease

Affiliations

Early Aberrant Angiogenesis Due to Elastic Fiber Fragmentation in Aortic Valve Disease

Robert B Hinton et al. J Cardiovasc Dev Dis. .

Abstract

Elastic fiber fragmentation (EFF) is a hallmark of aortic valve disease (AVD), and neovascularization has been identified as a late finding related to inflammation. We sought to characterize the relationship between early EFF and aberrant angiogenesis. To examine disease progression, regional anatomy and pathology of aortic valve tissue were assessed using histochemistry, immunohistochemistry, and electron microscopy from early-onset (<40 yo) and late-onset (≥40 yo) non-syndromic AVD specimens. To assess the effects of EFF on early AVD processes, valve tissue from Williams and Marfan syndrome patients was also analyzed. Bicuspid aortic valve was more common in early-onset AVD, and cardiovascular comorbidities were more common in late-onset AVD. Early-onset AVD specimens demonstrated angiogenesis without inflammation or atherosclerosis. A distinct pattern of elastic fiber components surrounded early-onset AVD neovessels, including increased emilin-1 and decreased fibulin-5. Different types of EFF were present in Williams syndrome (WS) and Marfan syndrome (MFS) aortic valves; WS but not MFS aortic valves demonstrated angiogenesis. Aberrant angiogenesis occurs in early-onset AVD in the absence of inflammation, implicating EFF. Elucidation of underlying mechanisms may inform the development of new pharmacologic treatments.

Keywords: angiogenesis; aortic root; elastic fiber; heart valves; pediatrics.

PubMed Disclaimer

Conflict of interest statement

The authors have no disclosure to make.

Figures

Figure 1
Figure 1
Aberrant angiogenesis in early-onset AVD precedes inflammation and atherosclerosis. Representative sections from control (left), early-onset AVD (center), and late-onset AVD (right) specimens. Normal elastic fiber structure is localized to the ventricularis layer of the cusp (arrow, A). Both early- and late-onset AVD are characterized by EFF and dispersion (B,C). Provisional (arrowhead) and overt (arrow) angiogenesis (D) is seen in early- (E) and late-onset (F) AVD, characterized in part by endothelial markers around neovessels (H,I) not observed in controls (G). Angiostatic CHM (J,K) is decreased in areas of angiogenesis in late-onset AVD (asterisk, L). Nominal CD-68 is seen in early-onset AVD (N), similar to control (M), corresponding with no atherosclerosis as demonstrated by absent LRP-5 staining (P,Q), both of which were markedly increased in late-onset AVD (double asterisks, O,R). The ventricularis cusp layer is oriented at the bottom of all panels.
Figure 2
Figure 2
Specific elastic fiber components are associated with overt angiogenesis. Representative sections from control (left column, A,C,E,G,I,K) and early-onset AVD (right column, B,D,F,H,J,L) specimens. In control tissue, elastin and fibulin-5 are localized in the cusp ventricularis layer (arrows), but fibrillin, emilin, fibulin-4, and LOX are also expressed weakly in all layers (arrowheads). In AVD tissue, elastin, fibrillin, emilin, and fibulin-4 are associated with neovessels (asterisk, B,D,F,H), whereas fibulin-5 and LOX are not (J,L).
Figure 3
Figure 3
Elastic fiber dysregulation impacts regional aortic valve structure. Regional aortic valve tissue (annulus, ring spongiosa, cusp) from control (A), early-onset AVD (B), WS (C), and MFS (D) specimens demonstrate specific differences in matrix organization. EFF in WS and MFS is different (arrows, C vs. D). Neovessels are seen in WS (arrowhead, C) but not MFS.
Figure 4
Figure 4
Ultrastructure of the valve annulus and cusp regions in WS and MFS. Collagen and elastic fiber organization in annulus (AC) and cusp (DF) regions from control (A,D), WS (B,E), and MFS (C,F) specimens. Cross sections of collagen fibril size and organization are demonstrated (insets). In control specimens, organized elastic fiber filaments are seen in the cusp (arrows) but not the annulus. WS specimens are characterized primarily by intra-EFF (B,E), whereas MFS has more inter-EFF (data not shown). There is proteoglycan accumulation in WS specimens (arrowheads, (B),(E)) and a “moth-eaten” edge appearance in MFS specimens (arrowheads, (C) and (F)). Collagen fibrils are small, irregular, and decreased in number in the cusp region of WS and the annulus region of MFS (asterisks, (C) and (E)).
Figure 5
Figure 5
Model of early EFF and angiogenesis preceding inflammation in AVD. Intact elastic fibers are organized as filaments in the normal ventricularis cusp layer (wavy black lines, A). Faulty elastic fiber assembly and/or imbalance between elastases and elastase inhibitors results in EFF (jagged black lines, (B). EFF causes angiogenesis (red circles), increased cell proliferation, and matrix accumulation (C), ultimately leading to inflammation (purple stars) and calcification (black nodules, D).

Similar articles

Cited by

  • Sex-specific role of galectin-3 in aortic stenosis.
    Matilla L, Martín-Núñez E, Garaikoetxea M, Navarro A, Tamayo I, Fernández-Celis A, Gainza A, Fernández-Irigoyen J, Santamaría E, Muntendam P, Álvarez V, Sádaba R, Jover E, López-Andrés N. Matilla L, et al. Biol Sex Differ. 2023 Oct 24;14(1):72. doi: 10.1186/s13293-023-00556-1. Biol Sex Differ. 2023. PMID: 37875993 Free PMC article.
  • Characterization of the sex-specific pattern of angiogenesis and lymphangiogenesis in aortic stenosis.
    Matilla L, Martín-Núñez E, Garaikoetxea M, Navarro A, Vico JA, Arrieta V, García-Peña A, Fernández-Celis A, Gainza A, Álvarez V, Sádaba R, López-Andrés N, Jover E. Matilla L, et al. Front Cardiovasc Med. 2022 Sep 12;9:971802. doi: 10.3389/fcvm.2022.971802. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36172587 Free PMC article.
  • Focusing on the Native Matrix Proteins in Calcific Aortic Valve Stenosis.
    Anousakis-Vlachochristou N, Athanasiadou D, Carneiro KMM, Toutouzas K. Anousakis-Vlachochristou N, et al. JACC Basic Transl Sci. 2023 Mar 29;8(8):1028-1039. doi: 10.1016/j.jacbts.2023.01.009. eCollection 2023 Aug. JACC Basic Transl Sci. 2023. PMID: 37719438 Free PMC article. Review.

References

    1. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. Lancet. 2006;368:1005–1011. doi: 10.1016/S0140-6736(06)69208-8. - DOI - PubMed
    1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., Dai S., Ford E.S., Fox C.S., Franco S., et al. Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association. Circulation. 2013;129:e28–e292. doi: 10.1161/01.cir.0000441139.02102.80. - DOI - PMC - PubMed
    1. Bonow R.O., Carabello B.A., Chatterjee K., de Leon A.C., Faxon D.P., Freed M.D., Gaasch W.H., Lytle B.W., Nishimura R.A., O’Gara P.T., et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2008;52:e1–e142. doi: 10.1016/j.jacc.2008.05.007. - DOI - PubMed
    1. Otto C.M. Valvular Aortic Stenosis: Disease Severity and Timing of Intervention. J. Am. Coll. Cardiol. 2006;47:2141–2151. doi: 10.1016/j.jacc.2006.03.002. - DOI - PubMed
    1. Rajamannan N.M., Evans F.J., Aikawa E., Grande-Allen K.J., Demer L.L., Heistad D.D., Simmons C.A., Masters K.S., Mathieu P., O’Brien K.D., et al. Calcific aortic valve disease: Not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Circulation. 2011;124:1783–1791. doi: 10.1161/CIRCULATIONAHA.110.006767. - DOI - PMC - PubMed

LinkOut - more resources